Screening Utility of the King-Devick Test in Mild Cognitive Impairment and Alzheimer Disease Dementia

The King-Devick (K-D) test is a 1 to 2 minute, rapid number naming test, often used to assist with detection of concussion, but also has clinical utility in other neurological conditions (eg, Parkinson disease). The K-D involves saccadic eye and other eye movements, and abnormalities thereof may be an early indicator of Alzheimer disease (AD)-associated cognitive impairment. No study has tested the utility of the K-D in AD and we sought to do so. The sample included 206 [135 controls, 39 mild cognitive impairment (MCI), and 32 AD dementia] consecutive subjects from the Boston University Alzheimer’s Disease Center registry undergoing their initial annual evaluation between March 2013 and July 2015. The K-D was administered during this period. Areas under the receiver operating characteristic curves generated from logistic regression models revealed the K-D test distinguished controls from subjects with cognitive impairment (MCI and AD dementia) [area under the curve (AUC)=0.72], MCI (AUC=0.71) and AD dementia (AUC=0.74). K-D time scores between 48 and 52 seconds were associated with high sensitivity (>90.0%) and negative predictive values (>85.0%) for each diagnostic group. The K-D correlated strongly with validated attention, processing speed, and visual scanning tests. The K-D test may be a rapid and simple effective screening tool to detect cognitive impairment associated with AD.

[1]  Laura J. Balcer,et al.  The King–Devick test and sports-related concussion: Study of a rapid visual screening tool in a collegiate cohort , 2011, Journal of the Neurological Sciences.

[2]  Alicia Peltsch,et al.  Saccade deficits in amnestic mild cognitive impairment resemble mild Alzheimer's disease , 2014, The European journal of neuroscience.

[3]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[4]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[5]  D. Salmon,et al.  The Alzheimer ’ s Disease Centers ’ Uniform Data Set ( UDS ) : The Neuropsychological Test Battery , 2009 .

[6]  Malaz Boustani,et al.  Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting , 2013, Alzheimer's & Dementia.

[7]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[8]  R. Green,et al.  Geriatric Performance on an Abbreviated Version of the Boston Naming Test , 2007, Applied neuropsychology.

[9]  Kewei Chen,et al.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study , 2012, The Lancet Neurology.

[10]  Jonathan M. Schott,et al.  Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy , 2014, Alzheimer's & Dementia.

[11]  Nathaniel Mercaldo,et al.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.

[12]  R. Green,et al.  Test–retest stability on the WRAT-3 reading subtest in geriatric cognitive evaluations , 2009, Journal of clinical and experimental neuropsychology.

[13]  K. R. Lou,et al.  Diagnostic Accuracy Statistics for Seven Neuropsychological Assessment Battery (NAB) Test Variables in the Diagnosis of Alzheimer's Disease , 2012, Applied neuropsychology. Adult.

[14]  S. Galetta,et al.  The King-Devick test for sideline concussion screening in collegiate football. , 2015, Journal of optometry.

[15]  S. Borson,et al.  The Mini‐Cog: a cognitive ‘vital signs’ measure for dementia screening in multi‐lingual elderly , 2000, International journal of geriatric psychiatry.

[16]  Adrian G. Palacios,et al.  Alzheimer's disease in the human eye. Clinical tests that identify ocular and visual information processing deficit as biomarkers , 2014, Alzheimer's & Dementia.

[17]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[18]  G. Fernández,et al.  Eye movement alterations during reading in patients with early Alzheimer disease. , 2013, Investigative ophthalmology & visual science.

[19]  D. Salmon,et al.  The neuropsychological profile of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[20]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[21]  J. Lucas,et al.  Diagnostic accuracy of the MMSE in detecting probable and possible Alzheimer's disease in ethnically diverse highly educated individuals: an analysis of the NACC database. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  B. Miller,et al.  Antisaccade task reflects cortical involvement in mild cognitive impairment , 2013, Neurology.

[23]  S. Galetta,et al.  The neuro-ophthalmology of head trauma , 2014, The Lancet Neurology.

[24]  D. Munoz,et al.  Age-related trends in saccade characteristics among the elderly , 2011, Neurobiology of Aging.

[25]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[26]  R. Caselli,et al.  Current epidemiology of mild cognitive impairment and other predementia syndromes. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[27]  D. Geldmacher,et al.  Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach. , 2013, The primary care companion for CNS disorders.

[28]  A. Mitchell,et al.  Screening and case finding tools for the detection of dementia. Part I: evidence-based meta-analysis of multidomain tests. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[29]  C. Gissane,et al.  Use of the King–Devick test for sideline concussion screening in junior rugby league , 2015, Journal of the Neurological Sciences.

[30]  Philip C. Ko,et al.  Eye movements in Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[31]  C. Adler,et al.  Slowing of number naming speed by King-Devick test in Parkinson's disease. , 2014, Parkinsonism & Related Disorders.

[32]  Amanda Connolly,et al.  Underdiagnosis of dementia in primary care: Variations in the observed prevalence and comparisons to the expected prevalence , 2011, Aging & mental health.

[33]  R. Green,et al.  Diagnostic utility of the NAB List Learning test in Alzheimer’s disease and amnestic mild cognitive impairment , 2009, Journal of the International Neuropsychological Society.

[34]  Jacob Cohen,et al.  A power primer. , 1992, Psychological bulletin.

[35]  S. Galetta,et al.  The King-Devick test as a concussion screening tool administered by sports parents. , 2014, The Journal of sports medicine and physical fitness.

[36]  S. Galetta,et al.  The King–Devick (K–D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS , 2014, Journal of the Neurological Sciences.

[37]  P. Lachenbruch Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[38]  Qing Yang,et al.  Specific saccade deficits in patients with Alzheimer’s disease at mild to moderate stage and in patients with amnestic mild cognitive impairment , 2012, AGE.

[39]  J. Galvin,et al.  Distinguishing Alzheimer’s disease from other major forms of dementia , 2011, Expert review of neurotherapeutics.